Brought to you by 
Illumina acquires CyVera
18 Apr 2005
Executive Summary
Looking to expand opportunities for its bead-based technology, particularly in diagnostics (a new arena for the company), Illumina (tools for large-scale analysis of genetic variation and function) is acquiring privately held CyVera (genomics/proteomics encoding technology). The purchase price is $17.5mm, consisting of $2.5mm in cash (includes payment of certain of CyVera's liabilities) and about 1.6mm of Illumina's common shares.
Deal Industry
- Pharmaceuticals
- Research, Analytical Equipment & Supplies
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
-
Drug Discovery Tools
- Genomics-Proteomics
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Intra-Biotech Deal
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Illumina acquires CyVera
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice